SARS-CoV2 variant-specific replicating RNA vaccines protect from disease and pathology and reduce viral shedding following challenge with heterologous SARS-CoV2 variants of concern

  1. David W Hawman  Is a corresponding author
  2. Kimberly Meade-White
  3. Jacob Archer
  4. Shanna S Leventhal
  5. Drew Wilson
  6. Carl Shaia
  7. Samantha Randall
  8. Amit P Khandhar
  9. Kyle Krieger
  10. Tien-Ying Hsiang
  11. Michael Gale Jr
  12. Peter Berglund
  13. Deborah Heydenburg Fuller
  14. Heinz Feldmann  Is a corresponding author
  15. Jesse Erasmus  Is a corresponding author
  1. National Institute of Allergy and Infectious Diseases, United States
  2. HDT Bio, United States
  3. University of Washington, United States
  4. The University of Washington, United States

Peer review process

This article was accepted for publication via eLife's original publishing model. eLife publishes the authors' accepted manuscript as a PDF only version before the full Version of Record is ready for publication. Peer reviews are published along with the Version of Record.

History

  1. Version of Record published
  2. Accepted Manuscript published
  3. Accepted
  4. Preprint posted
  5. Received

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. David W Hawman
  2. Kimberly Meade-White
  3. Jacob Archer
  4. Shanna S Leventhal
  5. Drew Wilson
  6. Carl Shaia
  7. Samantha Randall
  8. Amit P Khandhar
  9. Kyle Krieger
  10. Tien-Ying Hsiang
  11. Michael Gale Jr
  12. Peter Berglund
  13. Deborah Heydenburg Fuller
  14. Heinz Feldmann
  15. Jesse Erasmus
(2022)
SARS-CoV2 variant-specific replicating RNA vaccines protect from disease and pathology and reduce viral shedding following challenge with heterologous SARS-CoV2 variants of concern
eLife 11:e75537.
https://doi.org/10.7554/eLife.75537

Share this article

https://doi.org/10.7554/eLife.75537